Supergen, Inc

Simeon M Wrenn, Jr

Joseph Rubinfeld

Disclosed is a method of treating an HIV-infected host including administering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4&plus; T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4&plus; T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of treating an HIV-infected host including administering highly active antiretroviral therapy; and coadministering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4&plus; T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4&plus; T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of ex vivo or in vitro treatment of blood derived cells, bone marrow transplants, or other organ transplants including treating the blood derived cells, bone marrow transplants, or other organ transplants with a therapeutic agent that is cytotoxic or cytostatic with respect to CD4&plus; T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4&plus; T cell cytotoxic or cytostatic effective amount. Kits and compositions useful in the practice of the invention are also disclosed.

Treatment of HIV infections

Disclosed is a compound that includes a camptothecin conjugated to a lactone ring protecting moiety. Also disclosed are compositions and kits including the compound, and methods of making and using the compound.

Camptothecin conjugates

Disclosed are implants, stents, catheters, methods and kits for the local delivery of therapeutic agents that are preferentially cytotoxic or cytostatic with regards to proliferating cells to sites where proliferative cells are present.

Local delivery of therapeutic agents

Disclosed are compositions including an adenosine analog, wherein the composition comprises a dosage form suitable for oral (co)administration. Also disclosed are compositions including adenosine analogs, wherein the composition is in a dosage form including a pill, capsule, lozenge, or tablet, and compositions including adenosine analogs, wherein the composition is in a dosage form comprising a liquid. Additionally disclosed are methods of administering the inventive composition, and kits including the inventive compositions.

Growing community of inventors

Danville, CA, United States of America

Simeon M Wrenn, Jr